
Esophageal Cancer Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Description
Esophageal Cancer Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Summary
This reports provides a data-driven overview of the current and future competitive landscape in Esophageal Cancer therapeutics.
Synopsis
GlobalData’s Esophageal Cancer Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
Summary
This reports provides a data-driven overview of the current and future competitive landscape in Esophageal Cancer therapeutics.
Synopsis
- In 2022, there will be more than 440,000 diagnosed prevalent cases of esophageal cancer across 16 pharmaceutical markets.
- Currently there are four leading marketed innovator drugs for the treatment of esophageal cancer, mostly programmed cell death protein 1 (PD1) antagonists..
- A total of 14 pipeline drugs for esophageal cancer are in Phase III and two drugs are in pre-registration stage of development.
- Non-commercial sponsors dominate clinical trial development in esophageal cancer, with China emerging as the key country for conducting Phase III trials in this disease space.
- In deals involving companies developing esophageal cancer assets, there were 18 completed or announced strategic alliances and four merger and acquisition transactions.
- Emerging players in the esophageal cancer treatment space are focused on launching novel investigational drugs for treatment on a global scale.
GlobalData’s Esophageal Cancer Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Retail or Manufacturer Price of Products
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Esophageal Cancer market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Esophageal Cancer market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
73 Pages
- Key Findings
- Disease Overview
- Epidemiology Overview: Diagnosed Prevalent Cases of Esophageal Cancer in 2022 and
- Treatment Guidelines
- Marketed Drugs - Leading Marketed Drugs in Esophageal Cancer
- Marketed Drugs - Overview by Mechanism of Action
- Marketed Drugs - Overview by Route of Administration
- Marketed Drugs - Overview by Molecule Type
- Marketed Drug Profile: Merck & Co/MSD's Keytruda
- Marketed Drug Profile: Bristol Myers Squibb's Opdivo
- Marketed Drug Profile: Bristol Myers Squibb's Yervoy
- Marketed Drugs - Manufacturer Price (in $/mg) for Intravenous Formulations in Esophageal Cancer
- Marketed Drugs - Time to Pricing and Reimbursement for Pembrolizumab
- Marketed Drugs - Time to Pricing and Reimbursement for Nivolumab
- Marketed Drugs - Time to Pricing and Reimbursement for Ipilumab
- Pipeline Drugs Overview - Pre-registration and Phase III Pipeline Drugs in Esophageal Cancer
- Pipeline Drugs - Overview by Development Stage
- Pipeline Drugs - Overview by Mechanism of Action
- Pipeline Drugs - Overview by Route of Administration
- Pipeline Drugs - Overview by Molecule Type
- Pipeline Drugs - Drug-Specific Phase Transition Success Rate and Likelihood of Approval in Esophageal Cancer
- Pipeline Drugs - Phase Transition Success Rates and Likelihood of Approval in Oncology and in Esophageal Cancer
- Clinical Trials in Esophageal Cancer - Historical Overview
- Clinical Trials in Esophageal Cancer - Overview by Phase
- Clinical Trials in Esophageal Cancer - Overview by Status
- Clinical Trials in Esophageal Cancer - Overview by Phase for Ongoing and Planned Trial
- Clinical Trials in Esophageal Cancer - Trials with a Virtual Component
- Clinical Trials in Esophageal Cancer - Geographic Overview
- Clinical Trials in Esophageal Cancer - Single-Country and Multinational Trials by Region
- Clinical Trials in Esophageal Cancer - Top 20 Sponsors with Breakdown by Phase
- Clinical Trials in Esophageal Cancer - Top 20 Sponsors with Breakdown by Status
- Clinical Trials in Esophageal Cancer - Overview by Endpoint Status
- Clinical Trials in Esophageal Cancer - Overview by Race and Ethnicity
- Clinical Trials in Esophageal Cancer - Enrollment Data
- Clinical Trials in Esophageal Cancer - Overview of Sites by Geography
- Clinical Trials in Esophageal Cancer - Top 20 Countries for Trial Sites
- Clinical Trials in Esophageal Cancer - Top 10 Sites Globally
- Clinical Trials - Feasibility Analysis: Geography Overview
- Clinical Trials - Feasibility Analysis: Benchmark Models for Esophageal Cancer
- Deals Landscape - Mergers, Acquisitions, and Strategic Alliances in Esophageal Cancer by Region
- Commercial Assessment - Key Market Players in Esophageal Cancer
- Future Market Catalysts - Upcoming Market Catalysts in Esophageal Cancer
- Methodology
- Methodology - Sales Forecasts
- Methodology - Pricing and Reimbursement
- Methodology - Phase Transition Success Rate and Likelihood of Approval Analysis
- About the Authors
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.